Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 6 » Issue 1

Topiramate in the prevention and treatment of migraine: efficacy, safety and patient preference

Authors Steffen Naegel, Mark Obermann

Published Date December 2009 Volume 2010:6(1) Pages 17—28


Published 22 December 2009

Steffen Naegel, Mark Obermann

Department of Neurology, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany

Abstract: Migraine is a very common disorder characterized by the combination of typical headache with associated autonomic symptoms and/or the presence of aura. Considerable advances have been made in recent years to understand the pathophysiology of migraine, which has led to improved treatment options for the acute migraine attack as well as migraine prophylaxis. Unfortunately, preventive treatment is often insufficient to decrease migraine frequency substantially or is not well tolerated. Topiramate is an antipileptic drug with a complex mode of action which has proven its efficacy and safety in the prophylactic treatment of episodic migraine in a number of randomized controlled clinical trials. Topiramate is also effective in treating patients with chronic migraine. It has little pharmacological interaction with other drugs and is generally well tolerated by patients.

Keywords: migraine, antiepileptic drugs, topiramate

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Antimicrobial applications of nanotechnology: methods and literature

Seil JT, Webster TJ

International Journal of Nanomedicine 2012, 7:2767-2781

Published Date: 6 June 2012

Radio electric asymmetric brain stimulation in the treatment of behavioral and psychiatric symptoms in Alzheimer disease

Mannu P, Rinaldi S, Fontani V, Castagna A

Clinical Interventions in Aging 2011, 6:207-211

Published Date: 26 July 2011

The economic impact of obesity in the United States

Ross A Hammond, Ruth Levine

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010, 3:285-295

Published Date: 30 August 2010

Polyclonal light chains in cerebrovascular disease

Patrizia Fiori, Maria Giannetti Luigi, Linda Iurato, et al

Neuropsychiatric Disease and Treatment 2010, 6:533-537

Published Date: 24 August 2010

Effects of quetiapine on sleep architecture in patients with unipolar or bipolar depression

Laura Gedge, Lauren Lazowski, David Murray, et al

Neuropsychiatric Disease and Treatment 2010, 6:501-508

Published Date: 10 August 2010

Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo®)

Paolo Solla, Antonino Cannas, Francesco Marrosu, et al

Neuropsychiatric Disease and Treatment 2010, 6:483-490

Published Date: 4 August 2010

Current and emerging treatment options in the management of Friedreich ataxia

Michelangelo Mancuso, Daniele Orsucci, Anna Choub, et al

Neuropsychiatric Disease and Treatment 2010, 6:491-499

Published Date: 30 July 2010

Tenofovir-associated bone density loss

Iwen F Grigsby, Lan Pham, Louis M Mansky, et al

Therapeutics and Clinical Risk Management 2010, 6:41-47

Published Date: 24 December 2009

Local anesthetic failure associated with inflammation: verification of the acidosis mechanism and the hypothetic participation of inflammatory peroxynitrite

Takahiro Ueno, Hironori Tsuchiya, Maki Mizogami, Ko Takakura

Journal of Inflammation Research 2008, 1:41-48

Published Date: 13 November 2008